Menin Inhibition in Acute MLL-Rearranged Leukemias: A New Target for Precision Care

Download slides review a text module and read an expert commentary for expert perspectives on the importance and clinical application of emerging therapies targeting menin for patients with MLL-rearranged acute leukemias.

Share

Program Content

Activities

Menin Inhibitors in Leukemia: Module
Menin Inhibition in Acute MLL Rearranged Leukemias: A New Target for Precision Care
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: October 17, 2022

Expires: October 16, 2023

Menin Inhibitors in Leukemia: Slides
Menin Inhibition in Acute MLL Rearranged Leukemias: A New Target for Precision Care
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 17, 2022

Expires: October 16, 2023

Activities

Menin Inhibition
Menin Inhibition in the Treatment of MLL-Rearranged Acute Leukemias: A Promising New Strategy
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 26, 2022

Expires: October 25, 2023

Faculty

cover img faculity

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

cover img faculity

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Syndax